Substantial evidence indicates that the blood level of CCL23 can reflect the progression of several inflammatory diseases, including atherosclerosis, systemic mastocytosis, systemic sclerosis, acute myeloid leukemia, and chronic kidney disease (16–18). This evidence concerns the gene CCL23 and systemic mastocytosis.